CEO, Diamond Therapeutics
Judy Blumstock is CEO of Diamond Therapeutics who are developing FDA-approved, psilocybin-based therapeutics that deliver patient benefits without undesired perceptual side effects. Judy is also the Senior Director of Corporate Development at Toronto Innovation Acceleration Partners (TIAP), an early stage academic incubator. Prior to joining TIAP, Judith was a principal with Genesys Capital Partners, one of the largest Canadian-based venture-capital firms focused on the life sciences industry. She is also a past director of Insception, Millenium Biologix Corp., Plexagen Diagnostics, and Zelos Therapeutics Inc.